Quotazioni in diretta

ALNY Alnylam Pharmaceuticals Inc

150,47

-0,90 (-0,59%)

11 Mag 2024 - Chiuso

Dati in Delay di 15 minuti

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Grafico Azioni Alnylam Pharmaceuticals (NASDAQ:ALNY)
Storico
Da Apr 2024 a Mag 2024

Clicca qui per i Grafici di Alnylam Pharmaceuticals

Grafico Azioni Alnylam Pharmaceuticals (NASDAQ:ALNY)
Storico
Da Mag 2023 a Mag 2024

Clicca qui per i Grafici di Alnylam Pharmaceuticals

Notizie Alnylam Pharmaceuticals Inc - ALNY

Alnylam Issues 2023 Corporate Responsibility Report
Martedì 7 Maggio 2024 (5 giorni fa) • Business Wire

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
Giovedì 2 Maggio 2024 (1 settimana fa) • Business Wire

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Martedì 30 Aprile 2024 (2 settimane fa) • PR Newswire (US)

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Giovedì 18 Aprile 2024 (3 settimane fa) • Business Wire

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
Domenica 7 Aprile 2024 (1 mese fa) • Business Wire

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Mercoledì 20 Marzo 2024 (2 mesi fa) • Business Wire

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
Mercoledì 13 Marzo 2024 (2 mesi fa) • Business Wire

Alnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegen
Mercoledì 6 Marzo 2024 (2 mesi fa) • Business Wire

Alnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standards
Martedì 5 Marzo 2024 (2 mesi fa) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Martedì 5 Marzo 2024 (2 mesi fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Martedì 5 Marzo 2024 (2 mesi fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Martedì 5 Marzo 2024 (2 mesi fa) • Edgar (US Regulatory)

Più Alnylam Pharmaceuticals Inc Articoli Notizie

Intesa Sanpaolo

Banca Monte Dei Paschi D...

Mediobanca Banca di Cred...

ST Microelectronics

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea